Garetosmab, activin A inhibitor antibody for muscle-preservation combination regimens in obesity Recent Highlights: In June 2026, the company announced it would present new clinical data from the Phase 2 COURAGE trial that examines the effects of trevogrumab (anti-GDF8) on lean mass in people with obesity treated with semaglutide
Bang-Berthelsen CH, Holm TL, Pyke C, Simonsen L, Sokilde R, Pociot F, et al
For oral semaglutide (Rybelsus), the FDA prescribing information specifically notes increased thyroxine exposure when co-administered with levothyroxine
At first, it seemed like just stress, but the discomfort became more frequent, especially when lying down at night
Therapeutic Effects of Endogenous Incretin Hormones and Exogenous Incretin-Based Medications in Sepsis